[1]
|
Guillaume, T., Malard, F., Magro, L., Labopin, M., Tabrizi, R., Borel, C., Chevallier, P., Vigouroux, S., Peterlin, P., Garnier, A., Rubio, M.T., Huynh, A., Milpied, N., Moreau, P., Gaugler, B., Yakoub-Agha, I. and Mohty, M. (2019) Prospective Phase II Study of Prophylactic Low-Dose Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Bone Marrow Transplantation, 54, 1815-1826. https://doi.org/10.1038/s41409-019-0536-y
|
[2]
|
Guillaume, T., ThÉPot, S., Peterlin, P., Ceballos, P., Bourgeois, A.L., Garnier, A., Orvain, C., Giltat, A., François, S., Bris, Y.L., Fronteau, C., Planche, L. and Chevallier, P. (2021) Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse Following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Transplantation and Cellular Therapy, 27, 839.e1-839.e6. https://doi.org/10.1016/j.jtct.2021.06.029
|
[3]
|
Ramello, M.C., Benzaïd, I., Kuenzi, B.M., Lienlaf-Moreno, M., Kandell, W.M., Santiago, D.N., Pabon-Saldaña, M., Darville, L., Fang, B., Rix, U., Yoder, S., Berglund, A., Koomen, J.M., Haura, E.B. and Abate-Daga, D. (2019) An Immunoproteomic Approach to Characterize the CAR Interactome and Signalosome. Science Signaling, 12, Article eaap9777. https://doi.org/10.1126/scisignal.aap9777
|
[4]
|
Schneidawind, C., Jahnke, S., Schober-Melms, I., Schumm, M., Handgretinger, R., Faul, C., Kanz, L., Bethge, W. and Schneidawind, D. (2019) G-CSF Administration Prior to Donor Lymphocyte Apheresis Promotes Anti-Leukaemic Effects in Allogeneic HCT Patients. British Journal of Haematology, 186, 60-71. https://doi.org/10.1111/bjh.15881
|
[5]
|
Fozza, C., Szydlo, R.M., Abdel-Rehim, M.M., Nadal, E., Goldman, J.M., Apperley, J.F. and Dazzi, F. (2007) Factors for Graft-versus-Host Disease after Donor Lymphocyte Infusions with an Escalating Dose Regimen: Lack of Association with Cell Dose. British Journal of Haematology, 136, 833-836. https://doi.org/10.1111/j.1365-2141.2007.06501.x
|
[6]
|
王昱, 黄晓军. 移植后恶性血液病的复发及处理[M]//黄晓军, 刘代红, 吴德沛. 实用造血干细胞移植. 北京: 人民卫生出版社, 2014: 408-420.
|
[7]
|
Yang, L., Lai, X., Yang, T., Lu, Y., Liu, L., Shi, J., Zhao, Y., Wu, Y., Chen, Y., Yu, J., Xiao, H., Ouyang, G., Ren, J., Cao, J., Hu, Y., Tan, Y., Ye, Y., Cai, Z., Xu, W., Huang, H. and Luo, Y. (2024) Prophylactic versus Preemptive Modified Donor Lymphocyte Infusion for High-Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study. Bone Marrow Transplantation, 59, 85-92. https://doi.org/10.1038/s41409-023-02137-7
|
[8]
|
中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(II)——移植后白血病复发(2016年版). 中华血液学杂志, 2016, 37(10): 846-846. https://doi.org/10.3760/Cma.J.Issn.0253-2727.2016.10.004
|
[9]
|
Deol, A. and Lum, L.G. (2010) Role of Donor Lymphocyte Infusions in Relapsed Hematological Malignancies after Stem Cell Transplantation Revisited. Cancer Treatment Reviews, 36, 528-538. https://doi.org/10.1016/j.ctrv.2010.03.004
|
[10]
|
Frey, N.V. and Porter, D.L. (2008) Graft-versus-Host Disease after Donor Leukocyte Infusions: Presentation and Management. Best Practice & Research Clinical Haematology, 21, 205-222. https://doi.org/10.1016/j.beha.2008.02.007
|
[11]
|
Soiffer, R.J., Alyea, E.P., Hochberg, E., Wu, C., Canning, C., Parikh, B., Zahrieh, D., Webb, I., Antin, J. and Ritz, J. (2002) Randomized Trial of CD8 T-Cell Depletion in the Prevention of Graft-versus-Host Disease Associated with Donor Lymphocyte Infusion. Biology of Blood and Marrow Transplantation, 8, 625-632. https://doi.org/10.1053/bbmt.2002.v8.abbmt080625
|
[12]
|
Weissinger, E.M., Borchers, S., Silvani, A., Provasi, E., Radrizzani, M., Beckmann, I.K., Benati, C., Schmidtke, J., Kuehnau, W., Schweier, P., Luther, S., Fernandez-Munoz, I., Beutel, G., Ciceri, F., Bonini, C., Ganser, A., Hertenstein, B. and Stadler, M. (2015) Long Term Follow up of Patients after Allogeneic Stem Cell Transplantation and Transfusion of HSV-TK Transduced T-Cells. Frontiers in Pharmacology, 6, Article 76. https://doi.org/10.3389/fphar.2015.00076
|
[13]
|
Wei, Y.Q., Cen, X.N., Liu, H.H., Sun, Y.H., Shi, Y.J., Liu, W., Dong, Y.J. and Ren, H.Y. (2017) Irradiation of Peripheral Blood Mononuclear Cells with 7.5 Gy X-Rays Prior to Donor Lymphocyte Infusion Inhibits Proliferation While Preserving Cytotoxicity, and Improves the Effectiveness of HSCT in Patients with Hematological Malignancies. Oncology Letters, 13, 4101-4108. https://doi.org/10.3892/ol.2017.5966
|
[14]
|
Lulla, P.D., Naik, S., Vasileiou, S., Tzannou, I., Watanabe, A., Kuvalekar, M., Lulla, S., Carrum, G., Ramos, C.A., Kamble, R., Hill, L., Randhawa, J., Gottschalk, S., Krance, R., Wang, T., Wu, M., Robertson, C., Gee, A.P., Chung, B., Grilley, B., Brenner, M.K., Heslop, H.E., Vera, J.F. and Leen, A.M. (2021) Clinical Effects of Administering Leukemia-Specific Donor T Cells to Patients with AML/MDS after Allogeneic Transplant. Blood, 137, 2585-2597. https://doi.org/10.1182/blood.2020009471
|
[15]
|
Mo, X.D., Zhang, X.H., Xu, L.P., Wang, Y., Yan, C.H., Chen, H., Chen, Y.H., Han, W., Wang, F.R., Wang, J.Z., Liu, K.Y. and Huang, X.J. (2017) Comparison of Outcomes after Donor Lymphocyte Infusion with or without Prior Chemotherapy for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Annals of Hematology, 96, 829-838. https://doi.org/10.1007/s00277-017-2960-7
|
[16]
|
Tiribelli, M., Sperotto, A., Candoni, A., Simeone, E., Buttignol, S. and Fanin, R. (2009) Nilotinib and Donor Lymphocyte Infusion in the Treatment of Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph ALL) Relapsing after Allogeneic Stem Cell Transplantation and Resistant to Imatinib. Leukemia Research, 33, 174-177. https://doi.org/10.1016/j.leukres.2008.03.031
|
[17]
|
Botta, C., Caruso, N., Bossio, S., Storino, F., Console, G., Martino, M., Mendicino, F., Lucia, E., Morelli, R., Correale, P., Morabito, F., Gentile, M. and Vigna, E. (2020) Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in A Ph Acute Lymphoblastic Leukemia Patient in Molecular Relapse after Allogenic Stem Cell Transplant and Dasatinib: A Case Report. Frontiers in Oncology, 10, Article 967. https://doi.org/10.3389/fonc.2020.00967
|
[18]
|
Claiborne, J., Bandyopathyay, D., Roberts, C., Hawks, K., Aziz, M., Simmons, G., Wiedl, C., Chung, H., Clark, W., McCarty, J. and Toor, A. (2019) Managing Post Allograft Relapse of Myeloid Neoplasms: Azacitidine and Donor Lymphocyte Infusions as Salvage Therapy. Leukemia & Lymphoma, 60, 2733-2743. https://doi.org/10.1080/10428194.2019.1605066
|
[19]
|
PoirÉ, X., Graux, C., Ory, A., Herman, J., Baron, F., Schoemans, H., Lewalle, P., De Becker, A., Deeren, D., Berneman, Z., Kerre, T., Zachee, P., Selleslag, D. and Beguin, Y. (2022) Sequential Administration of Low Dose 5-Azacytidine (AZA) and Donor Lymphocyte Infusion (DLI) for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Relapse after Allogeneic Stem Cell Transplantation (SCT): A Prospective Study from the Belgian Hematology Society (BHS). Bone Marrow Transplantation, 57, 116-118. https://doi.org/10.1038/s41409-021-01464-x
|
[20]
|
Kalin, B., Van Norden, Y., Van Gelder, M., Breems, D., Maertens, J., Jongen-Lavrencic, M., Broers, A.E.C., Braakman, E., Grob, T., Zeijlemaker, W., Ossenkoppele, G.J., Meijer, E. and Cornelissen, J.J. (2020) Panobinostat and Decitabine Prior to Donor Lymphocyte Infusion in Allogeneic Stem Cell Transplantation. Blood Advances, 4, 4430-4437. https://doi.org/10.1182/bloodadvances.2020002074
|